

TCT-595

Early Healing After Treatment Of Coronary Lesions By Everolimus, Or Biolimus Eluting Bioresorbable Polymer Stents. One-month Results In The SORT-OUT VIII Optical Coherence Tomography Study

Ida R. Balleby¹, Niels R. Holm², Trine Ørhøj², Lisette Okkels Jensen³, Michael Maeng⁴, Lars Krusell¹, Christian J. Terkelsen², Jouke Dijkstra⁵, Anne Kaltoff⁶, Karsten T. Veien³, Lisbeth Antonsen⁷, Mikkel Hougaard³, Henning Kelbaek⁸, Lone K. Andersen⁹, Steen D. Kristensen², Hans Erik Botker¹⁰, Per Thayssen¹¹, Evald H. Christiansen¹², Jens F. Lassen¹³

¹Aarhus University Hospital, Skejby, Aarhus, Denmark, ²Aarhus University Hospital, Skejby, Aarhus N, Denmark, ³Odense University Hospital, Odense, Denmark, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Leiden University Medical Center, Leiden, The Netherlands, ⁶Dept. of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus, Denmark, ⁷Department of Cardiology, Odense University Hospital, Odense, Denmark, ⁸Skejby Hospital, University of Århus, Denmark, Copenhagen, Denmark, ⁹Aarhus University Hospital, Aarhus N, -, ¹⁰Aarhus University, Aarhus, NA, ¹¹NA, Odense, Denmark, ¹²Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N, Denmark, ¹³Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N, Denmark

Background: Improved early healing may reduce the risk of early stent thrombosis in patients treated with drug eluting stents. Incomplete healing is found more frequently after treatment for acute myocardial infarction, in patients with acute stent strut malapposition and after treatment by specific stent types. Dual antiplatelet therapy is used to balance the risk of incomplete healing but early discontinuation is rather common and hard to predict at the primary intervention. We aim to evaluate and compare early healing of an everolimus-eluting biodegradable polymer stent (Synergy, Boston Scientific, USA) having potential advantages in early healing with a biolimus-eluting biodegradable polymer stent (BioMatrix NeoFlex, Biosensors, Switzerland).

Methods: The study is a prospective, randomized dual center trial with one month follow-up (Cohort A) or three months follow-up (Cohort B). Patients are randomized 1:1 to Synergy or Biomatrix NeoFlex. A total of 160 patients are scheduled, 80 in each cohort. Inclusion criteria are stable angina pectoris, non-ST, or ST-elevation myocardial infarction. Exclusion criteria are impaired renal function, severe vessel tortuosity or severe systemic disease. Optical frequency domain imaging (OFDI, Lunawave, Terumo, Jp) will be acquired at baseline and at follow-up or earlier in case of a target vessel event. The primary endpoint is the Coronary Stent healing Index, a combination of uncovered apposed and malapposed struts, excess neointimal hyperplasia, acquired and persistent malapposition and size of the extra-stent lumen. Frame level matching is performed for baseline adjusted analysis by experienced observers using semi-automated software analysis (QCU-CMS Research, Leiden University Medical Center, The Netherlands). Clinical follow-up will be continued up to 5 years.

Results: One-month OFDI follow-up (Cohort A) will be presented at TCT2014.

Conclusions: The study is designed to compare early healing in two different stents. A potential difference may indicate improved early safety after stent implantation.

TCT-596

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience - Results from CENTURY II trial

Kazushige Kadota¹, William C. Wijns², Shigeru Saito³

¹Kurashiki Central Hospital, Kurashiki, Japan, ²Cardiovascular Center Aalst, Aalst, Belgium, ³Shonan Kamakura General Hospital, Kanagawa, Japan

Background: PCI with use of DES has been increasingly used in patients with high risk acute coronary syndromes (STEMI/NSTEMI). However, controversies related to their long-term safety in this complex patient population are still present. Therefore safety and efficacy of new, sirolimus-eluting stent coated with bioresorbable polymer, Ultimaster DES(Terumo Corporation, Tokyo, Japan), in high risk acute coronary syndrome (ACS) patients was assessed.

Methods: In the frame of a single-blind, randomized, multicentre CENTURY II study, out of 1123 patients enrolled, 264 have been diagnosed with high risk ACS and assigned randomly to treatment with Ultimaster (126) or Xience (138) DES. Primary endpoint of the study was TLF at 9 months. All data were 100% monitored and adverse events were adjudicated by an independent clinical event committee.

Results: Baseline patient characteristics such as age, gender, presence of diabetes, hypertension, dyslipidemia, family history of CAD, smoking, previous MI and previous PCI were similar in both study arms. Also, there were no differences noted in thrombus presence (10.1% vs 11.8%, p=0.61) or bifurcation lesions (10.2% vs 9.8%, p=0.88). LAD was the most frequent target vessel and radial access was used in >70% of cases, without difference between treatment arms. Clinical outcomes at 4-months are shown in the table below. No significant differences were observed between the two stent arms. There were 2 patients with subacute stent thrombosis in Ultimaster and 1 patient with 3 vessels of stent thrombosis in Xience arm, resulting in low and similar ST rates (1.6% vs 0.7%, p=0.51).

%	Cardiac death, %	MI, %	TLR, %	non TL-TVR	TLF, %	TVF, %
Ultimaster	0.0	1.6	1.6	0.0	3.2	3.2
Xience	0.0	3.6	0.7	2.2	3.6	5.1

Conclusions: Short term safety and efficacy of new Ultimaster DES was very similar to the Xience DES in patients with high risk ACS. Follow up of patients is ongoing and 1-year data will be available at the time of presentation.

TCT-597

Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials

John A. Ormiston¹, Alexandra Lansky², Dennis Donohoe³, Charlene Knappe³, Mathias Vrolix⁴, Stefan Verheyen⁵, Danny F. Schoors⁶, William C. Wijns⁷, ¹Mercy Angiography Unit, Auckland, New Zealand, ²Yale School of Medicine, New Haven, CT, ³Micell Technologies, Durham, NC, ⁴Ziekenhuis Oost-Limburg, Genk, Belgium, ⁵Antwerp Cardiovascular Center Middelheim, Antwerp, Belgium, ⁶University Hospital Brussels, Brussels, Belgium, ⁷Cardiovascular Research Center Aalst, Aalst, Belgium

Background: Unlike any other current bioabsorbable drug-eluting stent, the MiStent SES (Micell Technologies, Durham, NC) has a unique coating composition that allows for continued drug elution after the rapid and complete absorption of polymer. Crystalline sirolimus continues to maintain therapeutic drug tissue levels up to 9 months; 3 times longer than the presence of the polymer. The polymer coating is eliminated from a thin-strut (64µm) cobalt chromium stent in 45-60 days with complete tissue absorption within 90 days. Long-term clinical follow-up is important to confirm the continued safety of patients treated with DES in clinical practice. To date, patients from two studies have completed 3 year follow-up.

Methods: The DESSOLVE I clinical trial is a first-in-human study at 5 sites of 30 MiStent implanted patients; the DESSOLVE II clinical trial, is a 2:1 randomized study of 184 patients conducted at 26 sites in evaluating the MiStent SES as compared to the control stent, the Endeavor Sprint. In the trials, patients with discrete de novo lesions up to 27 mm in length in native coronary arteries were enrolled. In-stent late lumen loss (LLL) was evaluated in both trials and to date, patients have been followed for clinical events annually for 3-years. All MACE events, defined as all death, Q and non-Q wave myocardial infarction and all target vessel revascularization were adjudicated by an independent clinical events committee.

Results: Follow-up for DESSOLVE I was complete for all available patients at 3-years (29/29). No target lesion MACE events were reported through 3 years, however, 2 non-target vessel MIs were reported. In the DESSOLVE II trial, MACE for MiStent and Endeavor was 4.3% versus 6.7% (p=0.49) respectively at 9 months, 5.1% versus 8.3% (p=0.51) at 12 months and 6.7% versus 13.3% (p=0.167) at 2 years. Evaluation of additional 3-year clinical outcomes of the MiStent SES for DESSOLVE II will be presented.

Conclusions: The evaluation of a new DES (MiStent SES) with a distinctive coating to provide continuous drug elution in the absence of polymer reveals sustained clinical results through 3-years follow-up.

TCT-598

Randomized Comparison Between Self-Apposing Bare Metal AnD Paclitaxel-Eluting Coronary Stents For The Treatment Of Saphenous Vein Grafts (SVG): Results From The ADEPT Trial

Alexander J. IJsselmuiden¹, Giovanni Amoroso², Paul Vermeersch³,

Pasi P. Karjalainen⁴

¹Albert Schweitzer Hospital, Dordrecht, Netherlands, ²Onze Lieve Vrouw Gasthuis, Amsterdam, Netherlands, ³ZNA Middelheim, Antwerp, Belgium, ⁴Satakunta Central Hospital, Pori, Finland

Background: The advantages of saphenous vein are well known for CABG: it is used in 80% of these procedures. However Saphenous Vein Grafts (SVGs) get diseased over time because of thrombosis, intimal hyperplasia and atherosclerosis. PCIs of SVGs represent 10% of caseload in high volume cathlabs and carry increased risk compared to PCI in native vessels. Previous studies comparing DES with BMS showed reduced late lumen loss and target vessel revascularization, but also a higher mortality rate for DES: at the start of this study, no consensus was available. Moreover large lumen diameter and caliber change especially at the anastomosis site lead to increased risk of under- / over- sizing with balloon-expandable stents. Self-expanding stents could improve apposition after thrombus/debris resolution following PCI and their deployment from distal to proximal could limit risk of distal embolization.

Methods: The Adept study, a randomized multicenter study, compares the safety and performance of the STENTYS (STENTYS, France) coronary bare metal stent with the Paclitaxel-eluting stent in Saphenous Vein Graft lesions. Patients are followed up at 1, 6 and 12 months post-procedure. The primary endpoint is in-stent late lumen loss at 6 months, and secondary endpoints include MACE at 1, 6 and 12 months, binary restenosis at 6 months, and strut malapposition at 6 months (OCT substudy in 10 patients). Patients with de-novo lesion in SVG (>50%stenosis), under optimal drug regimen, and with

reference vessel graft diameter diameter ≥ 2.5 mm and ≤ 6 mm, were eligible for participation. Patients with cardiogenic shock and acute MI were excluded.

Results: 57 patients (27 BMS, 30 DES) were enrolled in 4 centers in 3 European countries. There was no distal embolization in both groups. MACEs rates at 1 and 6 months were resp. 3.7% and 11.1% in BMS group, and 3.3% and 10.0% in DES group. The patients in the DES group, found to be more complex, performed well compared to BMS group, although there was no statistical difference.

Conclusions: MACE at 12 months will be presented, as well as lumen loss and angiographic results at 6 months, and OCT follow-up at 6 months.

Stents - Drug-eluting: Novel Metallic DES

Washington Convention Center, Lower Level, Hall A

Saturday, September 13, 2014, 5:00 PM–7:00 PM

Abstract nos: 599-609

TCT-599

Final procedural, 30-day and 6-month angiographic, clinical and OCT outcomes from the DIRECT II Trial using the Svelte Integrated Delivery System with Enzymatic Bioabsorbable Sirolimus Coating

Stefan Verhey¹, Didier Carrié², Ahmed Khattab³, Ton Slagboom⁴, Jacques berland⁵, Jan Horak⁶, Mathias Vrolix⁷, Pieter C. Smits⁸, Victor M. Legrand⁹, Nicolas M. Van Mieghem¹⁰, Jean Fajadet¹¹, Joachim Schofer¹², Pieter R. Stella¹³
¹Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, Antwerp, Belgium, ²Cardiovascular and Metabolic Pole, Rangueil Hospital, Toulouse, France, ³Bern University Hospital, Bern, Switzerland, ⁴Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, ⁵clinique saint hilaire, rouen, France, ⁶General University Hospital, Prague 2, Prague, ⁷Hospital Oost Limburg, Genk, Limburg, ⁸Maasstad Hospital Rotterdam, Rotterdam, Netherlands, ⁹University hospital of Liege, LIEGE, Belgium, ¹⁰Erasmus MC, Rotterdam, Netherlands, ¹¹CLINIQUE PASTEUR, Toulouse, France, ¹²Medical Care Center Prof Mathey, Prof Schofer, Hamburg University Cardiovascular Center, Hamburg, Germany, ¹³University Medical Center Utrecht, Utrecht, Netherlands

Background: The Svelte (New Providence, NJ) sirolimus-eluting coronary stent utilizing a bioresorbable amino acid-based (PEA) drug carrier is mounted on a novel Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon control bands (BCBs) affixed to a 0.014 integrated wire with shapeable tip. The IDS is low-profile and specifically designed for use with the trans-radial approach (TRI), 'slender' PCI and direct stenting. The DIRECT I First-In-Man study (n=30) reports 2.7% stent volume obstruction (via IVUS) at 6-months with 0% clinically-driven MACE through 24-months. All events and imaging were reviewed and adjudicated by an independent core lab and DSMB.

Methods: 159 patients with symptomatic ischemic heart disease due to de novo stenotic lesions in arteries with RVD 2.5mm – 3.5mm and lesion length < 20 mm were prospectively randomized (2:1 Svelte IDS : Medtronic Resolute Integrity) at 18 sites in Europe. Clinical and angiographic follow-up was scheduled at 6-months to assess TVF and LL as well as multiple secondary endpoints, with clinical follow-up continuing through 5-years. Stent evaluation post-procedure and at 6-months via OCT was also performed in 30 patients. All events and imaging were reviewed and adjudicated by an independent core lab and DSMB.

Results: Study enrolment completed November 2013 (n=106 Svelte IDS arm, n=51 Medtronic Resolute Integrity); 6-month data on all available patients is expected May 2014. Procedural, 30-day and 6-month clinical and angiographic data on all patients, along with OCT image analysis (n=30), will be presented. Comparative data for time and cost savings, including TRI vs. femoral approach, procedure and device time, adjunctive product and contrast use, and radiation exposure, will be reported.

Conclusions: A review of the Svelte DES platform and available procedural, 30-day and 6-month angiographic, clinical and OCT outcomes from the study will be reported. These data provide first insights into the safety, efficacy and procedural efficiencies, as well as time and cost savings, of this unique DES IDS system compared with a prospective, matched control group utilizing a conventional DES system.

TCT-600

Distinct Vascular Response between Vulnerable and Stable Coronary Plaques after the Second Generation Drug-eluting Stents Implantation: One-year Angioscopic Comparison

Kenji Kawai¹, Minoru Ichikawa¹, Takashi Takagi¹, Mitsutoshi Asai¹, Yoshizumi Takei¹, Kenji Fukuda¹, Shohei Yoshima¹, Takeshi Oshita¹, Yoshiyuki Kijima¹
¹Higashi-osaka City General Hospital, Higashi-osaka, Osaka

Background: The second generation drug-eluting stents (G2-DES) have been implanted safely at culprit lesions not only of stable angina pectoris but also of acute coronary syndrome. The aim of this study was to angioscopically characterize vascular response after implantation of various G2-DES and to compare healing processes between stable and vulnerable plaques.

Methods: Enrolled were consecutive 64 patients who were successfully implanted with various G2-DES. Five patients were withdrawn from further analysis because of death or stroke. Coronary angiography at one year after stenting detected in-stent restenosis in 6 patients, who were excluded from further analysis. Subsequently, coronary angiography was performed in 63 lesions (32 vulnerable and 31 stable plaques) of 53 patients, revealing the in-stent appearance of each G2-DES, that is, [1] neointimal stent coverage (NSC, good/poor), [2] presence of thrombus (presence/absence), and [3] presence of yellow plaques (YP, presence/absence).

Results: In-stent thrombus was detected at only 1 vulnerable plaque implanted with BES. As shown in table, in both vulnerable and stable plaques, E-ZES was better covered with neointima than other G2-DES. In stable plaques, no significant differences were found in YP prevalence among G2-DES. In vulnerable plaques, however, prevalence of YP was significantly higher in BES than in another G2-DES.

Table. Angioscopic findings in G2-DES

Stable plaque					
	BES (n=6)	EES (n=11)	E-ZES (n=7)	R-ZES (n=7)	p-value
Good NSC (%)	16.7	45.5	100.0	28.6	0.01
Prevalence of YP (%)	16.7	18.2	0.0	0.0	0.43
Vulnerable plaque					
	BES (n=8)	EES (n=8)	E-ZES (n=5)	R-ZES (n=11)	p-value
Good NSC (%)	25.0	12.5	100.0	54.5	0.01
Prevalence of YP (%)	85.7	0.0	0.0	9.1	<0.0001
BES; biolimus-eluting stent, EES; everolimus-eluting stent, E-ZES; Endeavor zotarolimus-eluting stent, R-ZES; Resolute zotarolimus-eluting stent					

Conclusions: Vulnerable plaques implanted with BES remained yellowish and thrombogenic even at one year after stenting, suggesting the distinct vascular response after BES implantation at vulnerable plaques.

TCT-601

Comparison of sirolimus-eluting stents with biodegradable polymer versus zotarolimus-eluting stents with durable polymer assessed by optical coherence tomography: The ALSTER-OCT registry

Christian H. Heeger¹, Felix Lesche², Maximilian Fenski², Laura Hildebrand², Felix Meincke³, Andreas Busjahn⁴, Karl-Heinz Kuck⁵, Martin W. Bergmann⁶
¹St. Georg Department of Cardiology, Hamburg, Hamburg, ²St. Georg Department of Cardiology, Hamburg, Germany, ³Asklepios Klinik St. Georg, Hamburg, Hamburg, ⁴HealthTwiSt GmbH, Berlin, Berlin, ⁵Cardiology, Hamburg, Germany, ⁶Asklepios Clinic St. Georg, Hamburg, Germany

Background: Nevertheless the promising results of 2nd generation DES, recent findings suggest hypersensitivity reactions caused by the durable polymer coatings leading to chronic inflammation and possibly to late stent strut malapposition. Therefore new DES generations with improved biocompatibility and biodegradable polymers were introduced.

Methods: The registry aims to compare optical coherence tomography (OCT) based stent coverage at three, six and nine-months follow-up after PCI by 3rd generation Orsiro Hybrid sirolimus-eluting stents with biodegradable polymer (O-SES, Biotronik) and widely used 2nd generation zotarolimus-eluting stents with durable polymer (ZES, Endeavor™ Resolute™ and Resolute™ Integrity™, Medtronic Vascular). A total of 80 patients received implantation of O-SES (n=34) and ZES (n=46). Clinical driven OCT-analysis was performed at three, six or nine-months follow-up.